Synthetic dibenzylideneketones as promising anti-herpes simplex virus type 1 agents.

Archives of virology 2023 May 04

filter terms:

New antiviral agents for the treatment of herpes simplex virus type 1 (HSV-1) infection, which causes a highly prevalent and incurable disease, are needed. Here, we report for the first time the in vitro anti-HSV-1 activity of two dibenzylideneketone compounds: DBK1 and DBK2. DBK1 demonstrated virucidal activity, and high-resolution scanning electron microscopy showed that it caused morphological changes in the HSV-1 envelope. DBK2 was able to reduce HSV-1 plaque size in vitro. The DBKs are promising anti-HSV-1 candidates, as they exhibit low toxicity and exert an antiviral effect by acting at the early stages of HSV-1-host cell interaction. © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Citation

Thalita Zago Oliveira, Dyenefer Pereira Fonseca, André Henrique Dos Santos, Thays Rosa da Silva, Danielle Lazarin-Bidóia, Zia Ud Din, Benedito Prado Dias Filho, Celso Vataru Nakamura, Edson Rodrigues-Filho, Tania Ueda-Nakamura. Synthetic dibenzylideneketones as promising anti-herpes simplex virus type 1 agents. Archives of virology. 2023 May 04;168(5):153